



3 July 2019

COMPLETION OF ACQUISITION OF INTELLECTUAL PROPERTY

Invex Therapeutics Ltd (ACN 632 145 334) (**Company**) is pleased to advise all conditions precedent to the binding terms sheet, dated 12 March 2019 between the Company and The University of Birmingham, UK (**Agreement**), have been satisfied.

The Company has now been assigned the entire right, title and interest in the following intellectual property, in accordance with the contract of assignment of intellectual property dated 12 March 2019 between the Company and The University of Birmingham, UK (**Acquisition**):

- (a) international patent application PCT/GB2015/052453 (published as WO 2016/034851), claiming priority of GB 1415598.0;
- (b) any and all patent applications that claim priority to GB 1415598.0, including, without limitation, all national and regional parts thereof, including without limitation the applications listed below and including without limitation any and all continuations, continuations-in-part, divisional applications and substitute applications of any of the foregoing patent applications;
- (c) any and all patents issuing on any of the foregoing patent applications, including registrations, renewals, re-examinations, reissues, extensions, term restorations and supplementary protection certificates; and any and all foreign counterparts of any of the foregoing;
- (d) National and regional parts of PCT/GB2015/052453;
- (e) Patent applications published as:
 - (i) US 2017/0232073;
 - (ii) EP 3188747;
 - (iii) JP 2017/530955; and JP 2017/512008;
- (f) Orphan designation (EU/3/16/1629) granted by the European Commission to Alan Boyd Consultants Ltd, United Kingdom, for Exenatide for the treatment of idiopathic intracranial hypertension; and
- (g) Orphan Drug Designation 16-5305 granted by the US Department of Health & Human Services on 16 May 2017 for Exenatide for the treatment of idiopathic intracranial hypertension (submitted on behalf of Alan Boyd Consultants).

Board changes

At completion of the Acquisition, Dr Alexandra Sinclair was appointed as Executive Director and Chief Scientific Officer of the Company.